Bill Kerr of Avalon Heath Solutions says incorporating Z codes into CPT codes for lab and genetic testing would add needed specificity, reduce waste and possibly head off fraud.
|Slideshows|February 18, 2019
- Managed Healthcare Executive February 2019 Issue
- Volume 29
- Issue 2
Managed Care Technology Survey 2019
We asked healthcare industry leaders to tell us about how their organizations are using technology-from big data to remote monitoring devices. Here’s what they said.
Advertisement
Articles in this issue
over 7 years ago
The 4 Biggest New Areas to Focus on in 2019over 7 years ago
The State of Biosimilars in 2019over 7 years ago
Four Trends Health Execs Need to Follow in 2019over 7 years ago
Six Healthcare Technologies Coming in the Next 10 Yearsover 7 years ago
The Impact of Big Data on Medical Decisionsover 7 years ago
The Biggest Barrier to Home HealthcareAdvertisement
Related to this article
States have to turn that information into medical frailty determinations that are clinically credible, consistent, and workable across large Medicaid populations.
A meta-analysis found steatotic liver disease in 75% of patients with sleep-disordered breathing and that CPAP lowered liver enzymes but not liver fat.
Some predicted that drugmakers might boost launch prices to make up for Medicare drug negotiations shrinking profits. Harvard researchers find no evidence of that happening so far.
State PBM reform accelerates through 2026, with Theresa Carnegie of Mintz unpacking new laws, rebate pass-through, spread pricing bans, and compliance risks.
Only 19.1% of commercially insured patients with first-episode psychosis were adherent to antipsychotics in the year after starting treatment.
Prioritizing referral completion as much as referral generation will equip organizations to measure results and improve health outcomes.
Daiichi Sankyo and Merck pulled their bid for accelerated approval of I-DXd in small cell lung cancer after the FDA found phase 2 data fell short.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Tariffs on patented drugs now apply to all branded drugmakers
2
IRA drug price negotiation has not increased launch prices, study finds
3
FAQ: State PBM reform in 2026—What's new since spring
4
A head-to-head phase 3b comparison of bimekizumab with risankizumab in active psoriatic arthritis: Written recap
5